Saltar al contenido
PivotalWire
Miércoles 14 oct 2026SEC · NASDAQ biomédico

Portada›Miércoles 15 de octubre de 2025

Biomédicas del NASDAQ ante la SEC, miércoles 15 de octubre de 2025

Los 21 documentos que 19 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Por qué unas líneas van en color

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. BHSTBIOHARVEST SCIENCES INC.424B7Prospecto de reventa de tenedoresEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…Company, or otherwise at least as favorable to the Company as those previously obtained, or at all. Importantly, the inclusion in note 1B to the audited annual consolidated financial statements and in “Substantial Doubt About the Company’s Ability to Continue as a Going Concern” in the report thereto of Ziv Haft Certified Public Accountants (Isr.) (PCAOB ID# 1185) of disclosure regarding the Company’s ability to continue as a going concern may negatively impact the Company’s…
  2. CRSPCRISPR Therapeutics AG424B5Nueva emisión de acciones con precioEDGAR
  3. ELABPMGC Holdings Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…containing a microorganism transformed with a vector expressing myostatin and activin A on the cell surface as an active ingredient Going Concern As of December 31, 2024, management has determined there is substantial doubt about the Company’s ability to continue as a going concern. The Company may need to obtain funds to support its working capital, the methods of which include, without limitation, the following: ● this offering; ● other available sources of financing (including…
    En el documentoContrasplit de accionestexto original ▸…Skincare. On November 13, 2024, PMGC Capital LLC (“PMGC Capital”) was incorporated under the laws of the state of Nevada. PMGC is the sole shareholder of PMGC Capital. On November 27, 2024, the Company completed a reverse stock split on a ratio of two hundred old shares of common stock for every one new post reverse split common share. In addition, on March 10, 2025, the Company completed a second reverse stock split on a ratio of…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…does not purport to be complete and is subject to and are qualified in their entirety by a copy of the Northstrive Secondment Agreement, filed herein as Exhibit 10.32. 39 ● On April 24, 2025, the Company entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Univest Securities, LLC (“Univest”), under which the Company may issue and sell from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate…

Participaciones y control

  1. ARVNARVINAS, INC.SC 13D/ACambio en participación significativaEDGAR
  2. KALAKALA BIO, Inc.SC 13D/ACambio en participación significativaEDGAR
  3. KROSKeros Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
  4. PCSAProcessa Pharmaceuticals, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. QNRXQuoin Pharmaceuticals Ltd.8-KVenta de acciones no registrada (colocación privada)EDGAR
  2. APREAprea Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
  3. BIAFbioAffinity Technologies, Inc.8-KOtros hechos relevantesEDGAR
  4. CRSPCRISPR Therapeutics AG8-KOtros hechos relevantesEDGAR
  5. KROSKeros Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
  6. MIRAMIRA PHARMACEUTICALS, INC.8-KOtros hechos relevantesEDGAR
  7. NATRNATURES SUNSHINE PRODUCTS INC8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…Sunshine Products, Inc. (Nasdaq: NATR) (“Nature’s Sunshine”) (the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature’s Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with a proven track record of leading…
  8. OMEROMEROS CORP8-KNuevo acuerdo materialEDGAR
  9. SCYXSCYNEXIS INC8-KNuevo acuerdo materialEDGAR
    En el documentoAcuerdo de licencia o colaboracióntexto original ▸…exclusive license agreement and Binding 2023 MOU, together with the associated Transitional Manufacturing and Supply Agreement, the “Exclusive License Agreement”). Pursuant to the terms of the Exclusive License Agreement, SCYNEXIS granted GSK an exclusive (even as to SCYNEXIS and its affiliates), royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME®, for all indications, in all countries other than Greater…
  10. SYRESpyre Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
  11. VBIOValion Bio, Inc.8-KCambio en el consejo o la direcciónEDGAR
  12. XBITXBiotech Inc.8-K/ACambio en el consejo o la direcciónEDGAR

Juntas de accionistas

  1. LNAILunai Bioworks Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
  2. MRNAModerna, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.